Engage in ASCO’s Advocacy Efforts
Write a letter to your lawmaker today!
Related Articles
Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis
Key Points. Air pollution exposure is common, and may increase risk of developing blood clots.Greater long-term exposure to air pollution (i.e., PM2.5, NOx
‘My son spent his last morning begging for medication due to NHS 111 failures’Â
Charlie Marriage suffered a fatal seizure when he ran out of epilepsy medication across a weekend and failed to get a prescription despite several calls…
An AI system has reached human level on a test for ‘general intelligence’. Here’s what that means
OpenAI’s o3 model scored at human level on a benchmark test for artificial general intelligence – far higher than any results before.
How do brains coordinate activity? From fruit flies to monkeys, we discovered this universal principle
Are neurons star players, or do they prioritise teamwork? A new study has uncovered an answer for this long-standing debate about the brain.
The Reason Why Shingles Vaccine is Highly Protective Against Dementia
It may not have anything to do with shingles after all.
Osteoarthritis of the Knee Clinical Care Standard | Australian Commission on Safety and Quality in Health Care
The Osteoarthritis of the Knee Clinical Care Standard provides guidance to clinicians and healthcare service managers on how to diagnose and treat knee osteoarthritis.
All I want for Christmas is ethical, informative trials
Why the AQUILA trial is disappointing for patients and their loved ones
Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial | Blood Cancers Today
Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show robust clinical activity in NPM1-mutated AML.
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy…